PL2922867T3 - Sposób zwiększania objętości hydrodynamicznej polipeptydów przez przyłączanie peptydów końca karboksylowego gonadotropiny - Google Patents
Sposób zwiększania objętości hydrodynamicznej polipeptydów przez przyłączanie peptydów końca karboksylowego gonadotropinyInfo
- Publication number
- PL2922867T3 PL2922867T3 PL13856398T PL13856398T PL2922867T3 PL 2922867 T3 PL2922867 T3 PL 2922867T3 PL 13856398 T PL13856398 T PL 13856398T PL 13856398 T PL13856398 T PL 13856398T PL 2922867 T3 PL2922867 T3 PL 2922867T3
- Authority
- PL
- Poland
- Prior art keywords
- polypeptides
- attaching
- increasing
- carboxy terminal
- terminal peptides
- Prior art date
Links
- 101800005309 Carboxy-terminal peptide Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261728662P | 2012-11-20 | 2012-11-20 | |
EP13856398.6A EP2922867B1 (en) | 2012-11-20 | 2013-11-20 | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
PCT/IL2013/050960 WO2014080401A2 (en) | 2012-11-20 | 2013-11-20 | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2922867T3 true PL2922867T3 (pl) | 2021-12-06 |
Family
ID=50776635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13856398T PL2922867T3 (pl) | 2012-11-20 | 2013-11-20 | Sposób zwiększania objętości hydrodynamicznej polipeptydów przez przyłączanie peptydów końca karboksylowego gonadotropiny |
Country Status (20)
Country | Link |
---|---|
US (1) | US9808534B2 (pl) |
EP (2) | EP3848386A1 (pl) |
JP (2) | JP6416106B2 (pl) |
KR (2) | KR102341581B1 (pl) |
CN (3) | CN105121459A (pl) |
AU (1) | AU2013349239B2 (pl) |
BR (2) | BR122020018510B1 (pl) |
CA (1) | CA2891393A1 (pl) |
CL (1) | CL2015001347A1 (pl) |
EA (1) | EA033788B1 (pl) |
ES (1) | ES2882890T3 (pl) |
HU (1) | HUE055348T2 (pl) |
IL (1) | IL264700B (pl) |
MX (1) | MX363326B (pl) |
MY (1) | MY172997A (pl) |
PE (2) | PE20210171A1 (pl) |
PL (1) | PL2922867T3 (pl) |
PT (1) | PT2922867T (pl) |
SG (3) | SG10202010383YA (pl) |
WO (1) | WO2014080401A2 (pl) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
KR102118729B1 (ko) * | 2012-02-14 | 2020-06-05 | 옵코 바이오로직스 리미티드 | 장기 작용 응고 인자들 및 이를 생산하는 방법들 |
SG11201406671RA (en) * | 2012-04-19 | 2014-11-27 | Opko Biolog Ltd | Long-acting oxyntomodulin variants and methods of producing same |
CN105121459A (zh) | 2012-11-20 | 2015-12-02 | 奥普科生物制品有限公司 | 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法 |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
CN105461810A (zh) * | 2014-08-31 | 2016-04-06 | 复旦大学 | 一种长效的重组人粒细胞集落刺激因子的及其制备方法和用途 |
CA2914916A1 (en) * | 2014-12-10 | 2016-06-10 | Opko Biologics Ltd. | Methods of producing ctp-modified growth hormone polypeptides |
SG11201704706RA (en) * | 2014-12-10 | 2017-07-28 | Opko Biologics Ltd | Methods of producing long acting ctp-modified growth hormone polypeptides |
JP7096668B2 (ja) * | 2015-06-19 | 2022-07-06 | オプコ バイオロジクス リミテッド | 長時間作用型凝固因子およびその製造方法 |
CN106397570B (zh) * | 2015-07-31 | 2019-11-15 | 袁武梅 | 一种羧基末端肽及长效干扰素 |
CN106397571A (zh) * | 2015-07-31 | 2017-02-15 | 李金松 | 一种新型羧基末端肽及长效白介素7 |
CA3030533A1 (en) | 2016-07-11 | 2018-01-18 | Oren HERSHKOVITZ | Long-acting coagulation factor vii and methods of producing same |
CN107759697B (zh) * | 2016-08-19 | 2023-03-24 | 安源医药科技(上海)有限公司 | 制备融合蛋白的方法 |
CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
KR102675750B1 (ko) * | 2019-09-24 | 2024-06-18 | 엠브릭스 주식회사 | 항-바이러스 활성이 향상된 나노천공자 |
WO2021078834A1 (en) * | 2019-10-22 | 2021-04-29 | Genethon | Chimeric acid-alpha glucosidase polypeptides and uses thereof |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
JPS5781447A (en) | 1980-11-11 | 1982-05-21 | Toyo Jozo Co Ltd | Human chorionic gonadotropic hormone c-terminal fragment |
US4853332A (en) | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
DE3421468A1 (de) | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4911691A (en) | 1984-09-21 | 1990-03-27 | Menlo Care, Inc. | Assembly for adminstering IV solution |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
WO1989010756A1 (en) | 1988-05-06 | 1989-11-16 | Toray Industries, Inc. | STABLE INTERFERON beta COMPOSITION |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5338835A (en) | 1989-02-21 | 1994-08-16 | Washington University | CTP-extended form of FSH |
US5705478A (en) | 1989-02-21 | 1998-01-06 | Washington University | Covalently linked β subunits of the glycoprotein hormones as antagonists |
ES2098261T3 (es) | 1989-02-21 | 1997-05-01 | Univ Washington | Formas modificadas de hormonas reproductoras. |
US5792460A (en) * | 1989-02-21 | 1998-08-11 | Washington University | Modified glycoprotein hormones having a CTP at the amino terminus |
US6225449B1 (en) | 1991-10-04 | 2001-05-01 | Washington University | Hormone analogs with multiple CTP extensions |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US7217689B1 (en) | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
US5126324A (en) | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
US6028177A (en) | 1991-10-04 | 2000-02-22 | Washington University | Methods of detecting single-chain forms of the glycoprotein hormone quartet |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
JP4156024B2 (ja) | 1993-04-20 | 2008-09-24 | ワシントン ユニバーシティー | 修飾されたタンパク質及びペプチド医薬品 |
US5605976A (en) | 1995-05-15 | 1997-02-25 | Enzon, Inc. | Method of preparing polyalkylene oxide carboxylic acids |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US6737515B2 (en) | 1993-11-19 | 2004-05-18 | Washington University | Follicle stimulating hormone-glycosylation analogs |
US6238890B1 (en) | 1994-02-18 | 2001-05-29 | Washington University | Single chain forms of the glycoprotein hormone quartet |
US5935924A (en) | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
MX9601320A (es) | 1994-08-12 | 1997-05-31 | Univ Washington | Formas de cadena unica de cuarteto de hormona de glicoproteina. |
US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
US20050032211A1 (en) | 1996-09-26 | 2005-02-10 | Metabogal Ltd. | Cell/tissue culturing device, system and method |
TW518235B (en) | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
US6310183B1 (en) | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
US6103501A (en) | 1997-11-17 | 2000-08-15 | Washington University | Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof |
CA2343094A1 (en) | 1998-10-16 | 2000-04-27 | Biogen, Inc. | Interferon-beta fusion proteins and uses |
US6514729B1 (en) | 1999-05-12 | 2003-02-04 | Xencor, Inc. | Recombinant interferon-beta muteins |
PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
AU2001233299A1 (en) * | 2000-02-04 | 2001-08-14 | Esperion Therapeutics Inc. | Methods for treating alzheimer's disease |
US20020127652A1 (en) | 2000-02-11 | 2002-09-12 | Schambye Hans Thalsgard | Follicle stimulating hormones |
US7094566B2 (en) | 2000-03-16 | 2006-08-22 | Amgen Inc., | IL-17 receptor like molecules and uses thereof |
US20030036181A1 (en) | 2000-06-30 | 2003-02-20 | Okkels Jens Sigurd | Peptide extended glycosylated polypeptides |
US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
US6706289B2 (en) | 2000-10-31 | 2004-03-16 | Pr Pharmaceuticals, Inc. | Methods and compositions for enhanced delivery of bioactive molecules |
AU1384302A (en) | 2000-11-10 | 2002-05-21 | Proteopharma Aps | Apolipoprotein analogues |
JP4409135B2 (ja) | 2000-12-01 | 2010-02-03 | 武田薬品工業株式会社 | 生理活性物質含有製剤の製造法 |
AU2002224124A1 (en) | 2000-12-01 | 2002-06-11 | Takeda Chemical Industries Ltd. | Method for producing preparation containing bioactive substance |
MXPA03005036A (es) | 2000-12-07 | 2003-09-05 | Lilly Co Eli | Proteinas de fusion glp-1. |
KR101229995B1 (ko) * | 2000-12-11 | 2013-02-06 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
AU2002222740A1 (en) | 2000-12-11 | 2002-06-24 | Cheil Jedang Corporation | Fusion protein having the enhanced in vivo activity of erythropoietin |
EP1356809A4 (en) | 2000-12-28 | 2008-05-14 | Takeda Pharmaceutical | SUSTAINED RELEASE PREPARATIONS |
JP5160005B2 (ja) | 2000-12-28 | 2013-03-13 | 武田薬品工業株式会社 | 徐放性製剤 |
US6987172B2 (en) * | 2001-03-05 | 2006-01-17 | Washington University In St. Louis | Multifunctional single chain glycoprotein hormones comprising three or more β subunits |
US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
WO2002085311A2 (en) | 2001-04-25 | 2002-10-31 | Acevedo Hernan F | Hcg formulation |
US6824769B2 (en) | 2001-08-28 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Optimal compositions and methods thereof for treating HCV infections |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
JP4583029B2 (ja) | 2001-10-29 | 2010-11-17 | クルセル ホランド ベー ヴェー | 所定の翻訳後修飾を有する蛋白質の製造方法及び製造手段 |
KR100467751B1 (ko) * | 2001-12-03 | 2005-01-24 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
EP2261250B1 (en) | 2001-12-21 | 2015-07-01 | Human Genome Sciences, Inc. | GCSF-Albumin fusion proteins |
US7081446B2 (en) | 2002-01-31 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Long-acting follicle stimulating hormone analogues and uses thereof |
US7173113B2 (en) | 2002-01-31 | 2007-02-06 | The Trustees Of Columbia University In The City Of New York | Long-acting hormone and growth factor compositions and uses thereof |
GB0206048D0 (en) | 2002-03-14 | 2002-04-24 | Croda Int Plc | Use |
US20050256035A1 (en) * | 2002-05-13 | 2005-11-17 | Irving Boime | Ctp-extended erythropoietin |
US20070298041A1 (en) | 2002-06-28 | 2007-12-27 | Tomlinson Ian M | Ligands That Enhance Endogenous Compounds |
US20070025965A1 (en) | 2002-07-17 | 2007-02-01 | Lobb Roy R | Therapies for renal failure using interferon-beta |
US7459435B2 (en) | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
US8129330B2 (en) | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
JP4683319B2 (ja) | 2003-02-19 | 2011-05-18 | 武田薬品工業株式会社 | 徐放性製剤用の分散剤 |
US20060088595A1 (en) | 2003-02-19 | 2006-04-27 | Naoki Asakawa | Dispersant for sustained release preparations |
JP4698579B2 (ja) | 2003-04-08 | 2011-06-08 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 可逆的peg化薬物 |
EP2338333B1 (en) | 2003-04-09 | 2017-09-06 | ratiopharm GmbH | Glycopegylation methods and proteins/peptides produced by the methods |
WO2005035761A1 (en) | 2003-10-16 | 2005-04-21 | Compugen Ltd. | Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin |
WO2005047319A2 (en) | 2003-11-12 | 2005-05-26 | The University Of Georgia Research Foundation, Inc. | Dna sequence and expressed recombinant glycoproteins related to feline thyrotropin |
CN1901934B (zh) | 2003-12-19 | 2013-09-11 | 弗·哈夫曼-拉罗切有限公司 | 促红细胞生成素在治疗慢性炎症性肠病中铁分布紊乱中的用途 |
AU2005228945B2 (en) | 2004-03-19 | 2010-09-30 | Baxter Healthcare S.A. | Factor IXa for the treatment of bleeding disorders |
US20080206270A1 (en) | 2004-07-08 | 2008-08-28 | Minev Boris R | Enhancing Class I Antigen Presentation With Synthetic Sequences |
BRPI0514396A2 (pt) | 2004-08-17 | 2009-05-12 | Csl Behring Gmbh | polipeptìdeos dependentes de vitamina k modificada |
EP1802645A4 (en) | 2004-09-27 | 2009-01-14 | Cornell Res Foundation Inc | RECOMBINANT BIFUNCTIONAL PROTEIN FROM HUMAN LUTROPINE RECEPTOR, HUMAN CHORION GONADOTROPIN B SUBUNIT AND THEIR USES |
CN101724071A (zh) | 2004-10-08 | 2010-06-09 | 杜门蒂斯有限公司 | 抗肿瘤坏死因子受体1的单域抗体及其使用方法 |
GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
ES2385093T3 (es) | 2005-06-13 | 2012-07-18 | Imperial Innovations Limited | Análogos de oxintomodulina y sus efectos sobre el comportamiento de la conducta alimentaria |
WO2007047834A2 (en) | 2005-10-18 | 2007-04-26 | Biocon Limited | Oral peptide conjugates for metabolic diseases |
US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US8304386B2 (en) | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8759292B2 (en) * | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
US8048849B2 (en) * | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
WO2007092252A2 (en) | 2006-02-03 | 2007-08-16 | Modigene Inc | Long-acting polypeptides and methods of producing same |
EP1991574B1 (en) | 2006-02-22 | 2016-10-12 | Merck Sharp & Dohme Corp. | Oxyntomodulin derivatives |
TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
EP2423306A1 (en) | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
AT505262A1 (de) | 2007-06-12 | 2008-12-15 | Apeiron Biolog Forschungs Und | Rekombinantes ace2 polypeptid |
CN101952421A (zh) | 2007-12-05 | 2011-01-19 | 诺维信公司 | 具有内切葡聚糖酶活性的多肽和编码所述多肽的多核苷酸 |
RU2526804C2 (ru) | 2008-08-06 | 2014-08-27 | Ново Нордиск Хелс Кеа Аг | Конъюгированные белки с пролонгированным действием in vivo |
EP2898900B1 (en) | 2008-09-19 | 2017-11-15 | Nektar Therapeutics | Polymer conjugates of ziconotide |
KR20120003443A (ko) | 2009-02-27 | 2012-01-10 | 피르마 귀링 오하게 | 모듈형 자동 공구 공급기 |
US8828953B2 (en) | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
DE102009031992A1 (de) | 2009-07-06 | 2011-01-13 | Paul Hartmann Ag | Vorrichtung zur Unterdrucktherapie von Wunden |
AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
CA2837710C (en) | 2011-06-02 | 2022-11-08 | Prolor Biotech Inc. | Pegylated oxyntomodulin conjugates with improved linkers |
SG11201406671RA (en) * | 2012-04-19 | 2014-11-27 | Opko Biolog Ltd | Long-acting oxyntomodulin variants and methods of producing same |
KR102092025B1 (ko) | 2012-06-04 | 2020-03-24 | 옵코 바이오로직스 리미티드 | 페길화된 옥신토모둘린 변이체 |
CN105121459A (zh) | 2012-11-20 | 2015-12-02 | 奥普科生物制品有限公司 | 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法 |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
-
2013
- 2013-11-20 CN CN201380066354.XA patent/CN105121459A/zh active Pending
- 2013-11-20 PE PE2020000890A patent/PE20210171A1/es unknown
- 2013-11-20 MY MYPI2015001338A patent/MY172997A/en unknown
- 2013-11-20 EP EP21151437.7A patent/EP3848386A1/en active Pending
- 2013-11-20 ES ES13856398T patent/ES2882890T3/es active Active
- 2013-11-20 AU AU2013349239A patent/AU2013349239B2/en active Active
- 2013-11-20 SG SG10202010383YA patent/SG10202010383YA/en unknown
- 2013-11-20 BR BR122020018510-4A patent/BR122020018510B1/pt active IP Right Grant
- 2013-11-20 PL PL13856398T patent/PL2922867T3/pl unknown
- 2013-11-20 PT PT138563986T patent/PT2922867T/pt unknown
- 2013-11-20 CN CN202011589444.5A patent/CN112661863A/zh active Pending
- 2013-11-20 EP EP13856398.6A patent/EP2922867B1/en active Active
- 2013-11-20 HU HUE13856398A patent/HUE055348T2/hu unknown
- 2013-11-20 PE PE2015000654A patent/PE20151087A1/es unknown
- 2013-11-20 SG SG10201610223PA patent/SG10201610223PA/en unknown
- 2013-11-20 BR BR112015011583-7A patent/BR112015011583B1/pt active IP Right Grant
- 2013-11-20 MX MX2015006302A patent/MX363326B/es unknown
- 2013-11-20 CA CA2891393A patent/CA2891393A1/en active Pending
- 2013-11-20 WO PCT/IL2013/050960 patent/WO2014080401A2/en active Application Filing
- 2013-11-20 US US14/085,221 patent/US9808534B2/en active Active
- 2013-11-20 SG SG11201503879QA patent/SG11201503879QA/en unknown
- 2013-11-20 KR KR1020217000464A patent/KR102341581B1/ko active IP Right Grant
- 2013-11-20 CN CN202210004843.3A patent/CN114317505A/zh active Pending
- 2013-11-20 JP JP2015542413A patent/JP6416106B2/ja active Active
- 2013-11-20 KR KR1020157016362A patent/KR102202255B1/ko active IP Right Grant
- 2013-11-20 EA EA201590994A patent/EA033788B1/ru unknown
-
2015
- 2015-05-19 CL CL2015001347A patent/CL2015001347A1/es unknown
-
2018
- 2018-10-03 JP JP2018188424A patent/JP2019038812A/ja active Pending
-
2019
- 2019-02-06 IL IL264700A patent/IL264700B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL264700B (en) | A method for increasing the hydrodynamic volume of a polypeptide by linking peptides through their carboxyl end to gonadotropin | |
IL285015A (en) | Recombinant cell surface capture proteins | |
HK1204799A1 (en) | Waterproofing membrane | |
HK1206748A1 (en) | Modified polynucleotides for the production of membrane proteins | |
EP2940135A4 (en) | HETERODIMERIZED POLYPEPTIDE | |
EP2797634A4 (en) | MODIFIED mRNA ENCODING POLYPEPTIDES PENETRATING IN CELLS | |
HK1213521A1 (zh) | 多肽的應用 | |
GB201012988D0 (en) | Dehydration of liquid fuel | |
HK1204488A1 (en) | Electrochemical compression system | |
HK1208810A1 (en) | C-terminal and central epitope a-beta antibodies c a- | |
GB201222833D0 (en) | Detection of membrane proteins | |
HK1198926A1 (en) | Tyrosine based linkers for the releasable connection of peptides | |
EP2824741A4 (en) | ELECTROLYTE FILM ELECTRODE ARRANGEMENT | |
SG10201501080VA (en) | Method For The Determination Of Sequence Variants Of Polypeptides | |
GB201220021D0 (en) | Fuel cell components | |
SG11201504860PA (en) | Porous metallic membrane | |
GB201220017D0 (en) | Fuel cell components | |
HUP1200171A1 (hu) | Módszerek polipeptidek elõállítására | |
EP2874219A4 (en) | Membrane electrode assembly | |
GB201220036D0 (en) | Fuel cell components | |
IL238904B (en) | A method for increasing the hydrodynamic volume of a polypeptide by linking peptides through their carboxyl end to gonadotropin | |
EP2849793A4 (en) | Infliximab AFFINITY PEPTIDE | |
GB201204065D0 (en) | Fusion polypeptide | |
GB201215288D0 (en) | Improvements relating to firelighters |